Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 5/20 | 0.54 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.54 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.54 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27826314 | 1.00 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL19670 | 0.97 | LMNA (0.59) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL5549033 | 0.97 | LMNA (0.59) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL6918769 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL6915968 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| Methane SCHEMBL7758417 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL8714156 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL313548 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL6914844 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR | |
| SCHEMBL6914848 | 0.95 | LMNA (0.56) | LMNAMEN1KMT2ACA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105873913-B | Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins | 得克萨斯系统大学评议会 | 2019-12-03 | — | — | CN | disclosed |
| CN-107108637-B | Triazolopyrimidine compound and application thereof | NOVARTIS AG (CH) | 2019-10-29 | — | — | CN | disclosed |
| CN-108129454-B | A kind of benzenesulfonamides and its preparing the application in anti-influenza A virus medicament | 武汉大学 | 2019-09-17 | — | — | CN | disclosed |
| CN-109790166-A | imidazopyridine compounds for the treatment of cancer | 诺华股份有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109705015-A | Histon deacetylase (HDAC) inhibitor and preparation method thereof and purposes | 成都先导药物开发有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-105189497-B | N- (2- cyano heterocycle) Pyrazolopyridine ketone as JANUS kinase inhibitor | 默沙东公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109563103-A | modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-109415381-A | Thiazolopyridine derivatives as GPR119 agonist | 人类制药有限公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-105189508-B | Naphthenic base nitrile Pyrazolopyridine ketone as JANUS kinase inhibitor | 默沙东公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108697811-A | Inhibition of ataxia telangiectasia and Rad 3-related protein (ATR) | 梅里麦克制药股份有限公司 | 2018-10-23 | — | — | CN | disclosed |
| EP-1313737-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002010168-A1 | NOVEL GUANIDINO DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-07 | — | — | WO | disclosed |
| EP-1176145-A1 | Novel guanidino derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2002-01-30 | — | — | EP | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
| US-5681961-A | TREATMENT AND/OR PREVENTION OF THROMBOEMBOLIC DISORDERS, ARTERIOSCLEROSIS, METASTASIS. ISCHEMIA, ASTHMA, ALLERGIES | DR. KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| US-5625067-A | Cyclopentane ether derivatives, processes for their production, and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-29 | — | — | US | disclosed |
| US-5426119-A | Thromboxane antagonists | DR. KARL THOMAE GMBH (DE) | 1995-06-20 | — | — | US | disclosed |
| US-5294626-A | Thromboxane synthesis inhibitors and anticoagulants | DR. KARL THOMAS GMBH (DE) | 1994-03-15 | — | — | US | disclosed |
| EP-0450585-A2 | Process for the manufacture of 2-deoxy-D-threo-pentofuranosides, intermediates for their manufacture and their use | CHEMPROSA, CHEMISCHE PRODUKTE SAISCHEK GmbH (AT) | 1991-10-09 | — | — | EP | disclosed |
| US-5021543-A | Process for the production of bifunctional OH-terminated polyphenylene oxides with dipolar aprotic solvent | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | CA2 1511/4885MMP1 897/4885MMP8 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.